M
Miguel F. Sanmamed
Researcher at University of Navarra
Publications - 129
Citations - 10078
Miguel F. Sanmamed is an academic researcher from University of Navarra. The author has contributed to research in topics: Immunotherapy & Medicine. The author has an hindex of 38, co-authored 102 publications receiving 6150 citations. Previous affiliations of Miguel F. Sanmamed include Chartered Institute of Management Accountants & Yale University.
Papers
More filters
Journal ArticleDOI
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed,Lieping Chen +1 more
TL;DR: The principles of immune normalization are highlighted and lessons learned are learned to guide better designs for future cancer immunotherapies.
Journal ArticleDOI
Cytokines in clinical cancer immunotherapy
Pedro Berraondo,Miguel F. Sanmamed,Maria C. Ochoa,Iñaki Etxeberria,Maria Angela Aznar,Jose Luis Perez-Gracia,Maria E. Rodriguez-Ruiz,Mariano Ponz-Sarvise,Eduardo Castanon,Ignacio Melero +9 more
TL;DR: The novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials are provided, including known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells.
Journal ArticleDOI
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang,Miguel F. Sanmamed,Ila Datar,Tina Tianjiao Su,Lan Ji,Jingwei Sun,Ling Chen,Yusheng Chen,Gefeng Zhu,Weiwei Yin,Linghua Zheng,Ting Zhou,Ti Badri,Sheng Yao,Shu Zhu,Agedi Boto,Mario Sznol,Ignacio Melero,Dario A. A. Vignali,Kurt A. Schalper,Lieping Chen,Lieping Chen +21 more
TL;DR: It is demonstrated that fibrinogen-like protein 1 (FGL1), a liver-secreted protein, is a major LAG-3 functional ligand independent from MHC-II, revealing an immune evasion mechanism and have implications for the design of cancer immunotherapy.
Journal ArticleDOI
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott N. Gettinger,Jungmin Choi,Katherine Hastings,Anna Truini,Ila Datar,Ryan T. Sowell,Anna Wurtz,Weilai Dong,Guoping Cai,Mary Ann Melnick,Victor Y. Du,Joseph Schlessinger,Sarah B. Goldberg,Anne C. Chiang,Miguel F. Sanmamed,Ignacio Melero,Jackeline Agorreta,Luis M. Montuenga,Richard P. Lifton,Soldano Ferrone,Paula B. Kavathas,David L. Rimm,Susan M. Kaech,Kurt A. Schalper,Roy S. Herbst,Katerina Politi +25 more
TL;DR: CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs.
Journal ArticleDOI
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs,Jose Luis Perez-Gracia,Ana Rouzaut,Miguel F. Sanmamed,Agnes Le Bon,Ignacio Melero +5 more
TL;DR: Type I interferons are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR), and cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described.